BioCentury | Aug 18, 2014
Clinical News

Teysuno tegafur/gimeracil/oteracil potassium: Phase III data

...Ltd. , Tokyo, Japan Product: Teysuno tegafur/gimeracil/oteracil potassium (S-1, TS-1 ) Business: Cancer Molecular target: Dihydropyrimidine dehydrogenase...
BioCentury | Jun 3, 2013
Strategy

Taiho goes global

...oral combination of tegafur and uracil, a pyrimidine that improves the drug's half-life by inhibiting dihydropyrimidine dehydrogenase...
...for solid tumors. TAS-114 is a first-in-class dual inhibitor of deoxyuridine 5'-triphosphate nucleotidehydrolase (dUTPase) and dihydropyrimidine dehydrogenase...
BioCentury | Mar 11, 2013
Regulation

Dissecting Kadcyla

...polymerase (PARP) Ph II Adherex Technologies Inc. (TSX:AHX; OTC:ADHXF)/ GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) Eniluracil (ADH300004) Dihydropyrimidine dehydrogenase...
BioCentury | Jan 14, 2013
Clinical News

Eniluracil: Completed Phase II enrollment

...N.C. GlaxoSmithKline plc (LSE:GSK; NYSE:GSK), London, U.K. Product: Eniluracil Business: Cancer Molecular target: Dihydropyrimidine dehydrogenase Description: Dihydropyrimidine dehydrogenase...
BioCentury | Dec 17, 2012
Clinical News

Eniluracil: Interim Phase II data

...N.C. GlaxoSmithKline plc (LSE:GSK; NYSE:GSK), London, U.K. Product: Eniluracil Business: Cancer Molecular target: Dihydropyrimidine dehydrogenase Description: Dihydropyrimidine dehydrogenase...
BioCentury | Aug 13, 2012
Emerging Company Profile

Inform Genomics: SNPing side effects

...chemotherapy-induced toxicity. For example, OnDose from Myriad Genetics Inc. detects variations in the genes encoding dihydropyrimidine dehydrogenase...
BioCentury | Apr 11, 2011
Clinical News

Eniluracil: Phase II started

...N.C. GlaxoSmithKline plc (LSE:GSK; NYSE:GSK), London, U.K. Product: Eniluracil Business: Cancer Molecular target: Dihydropyrimidine dehydrogenase Description: Dihydropyrimidine dehydrogenase...
BioCentury | Jul 13, 2009
Company News

Adherex cancer news

...Martin; Fred Mermelstein; Peter Morand; and Robin Norris resigned (see BioCentury, April 6). Eniluracil, a dihydropyrimidine dehydrogenase...
BioCentury | Nov 24, 2008
Clinical News

Eniluracil: Phase I suspended enrollment

...N.C. GlaxoSmithKline plc (LSE:GSK; NYSE:GSK), London, U.K. Product: Eniluracil Business: Cancer Molecular target: Dihydropyrimidine dehydrogenase Description: Dihydropyrimidine dehydrogenase...
BioCentury | Nov 24, 2008
Clinical News

Eniluracil: Phase I/II suspended enrollment

...N.C. GlaxoSmithKline plc (LSE:GSK; NYSE:GSK), London, U.K. Product: Eniluracil Business: Cancer Molecular target: Dihydropyrimidine dehydrogenase Description: Dihydropyrimidine dehydrogenase...
Items per page:
1 - 10 of 26